Foreign Exchange Rate Risk

「Ordinary income increased 108.7% year on year to ¥120.147 million, owing to the recognition of foreign exchange gains and other items.」

「The company recorded a ¥6.131 million foreign exchange gain as non-operating income.」

「Foreign exchange gains — 6,131」

「Foreign exchange gains ― 407」

「During the consolidated fiscal year, the company recorded electricity sales revenue and royalty income, while also recording interest expense and a foreign exchange loss. Ordinary income increased 67.3% year on year to ¥209.861 million.」

「Foreign exchange losses ― 5,568」

「During the consolidated fiscal year, the yen generally weakened from the beginning to the end of the fiscal year, resulting in an ¥8.702 million foreign exchange gain on foreign-currency-denominated trade receivables and other assets.」

「During the consolidated fiscal year, the yen generally weakened from the beginning to the end of the fiscal year, resulting in a ¥4.559 million foreign exchange gain on foreign-currency-denominated trade receivables and other assets.」

「Foreign exchange gains ─ 8,937」

「Foreign exchange gains ─ 5,661」

「Foreign exchange losses 4,429 31」

「Foreign exchange losses 1,621 319」

「In non-operating income and expenses, the company recorded a ¥90.944 million loss on investments accounted for under the equity method, but also recorded a ¥4.849 million foreign exchange gain. As a result, the ordinary loss was ¥310.511 million, compared with an ordinary loss of ¥678.762 million in the same period of the previous year.」

「Foreign exchange losses 847 7,840」

「Foreign exchange losses 2,420 4,429」

「Foreign exchange losses 2,377 1,621」

「The Group does not hedge the risk associated with foreign-currency-denominated operating receivables and payables using derivatives because the amounts of such receivables and payables are not material.」

「Foreign exchange gains 4,256 ─ Foreign exchange losses ─ 847」

「Foreign exchange gains 5,466 ─ Foreign exchange losses ─ 2,420」

「Foreign exchange gains 2,303 ─ Foreign exchange losses ─ 2,377」

「In ordinary income and expenses, the ordinary loss was ¥155.747 million, compared with an ordinary loss of ¥49.013 million in the same period of the previous year, due in part to grant income from the government for research projects in the genetically modified silkworm business and the recognition of foreign exchange gains.」

「In non-operating income and expenses, the US dollar exchange rate was slightly weaker against the yen than at the end of the previous fiscal year, generating foreign exchange gains on foreign-currency-denominated assets and receivables. As a result, the ordinary loss was ¥35.624 million, compared with an ordinary loss of ¥59.976 million in the same period of the previous year.」

「The ordinary loss was ¥49.013 million, compared with an ordinary loss of ¥1,170.355 million in the same period of the previous year. Although royalty income from the use of patents and other intellectual property owned by the Company was recorded as revenue, a foreign exchange loss was also recorded as a result of translating foreign-currency-denominated assets and liabilities, reflecting the recent trend toward a stronger yen.」

「At present, the Group does not hedge foreign exchange risk through forward contracts or other means, so exchange-rate movements could affect the Group's operating results.」

「In the research-related business, sales of antibody-related reagents, the Group's core products, performed well in Japan but declined overseas due to the stronger yen and other factors.」

「At present, the Group does not hedge foreign exchange risk through forward contracts or other means, so exchange-rate movements could affect the Group's operating results.」